Blend Labs Inc (BLND) (Q3 2026) Earnings Call Highlights: Autopilot Momentum and Record

Blend Labs (BLND) reported Q3 2026 earnings, lowering Q4 revenue guidance to $27.7-29.7M (down 8-15% YoY) due to a deteriorating mortgage market. Mortgage suite revenue declined 2% YoY in Q3 and is expected to drop 23-28% in Q4. Non-GAAP gross margin fell to 77.2% due to Autopilot model costs. Autopilot deals face delays due to compliance, with potential $5M revenue contribution in 2027. Consumer Banking outperformed, driven by home equity, but macro pressures persist.

Original reporting
Published Nov 6, 2026, 5:25 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 5:41 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Blend Labs Inc (BLND) (Q3 2026) Earnings Call Highlights: Autopilot Momentum and Record — source image
Decision brief

The 30-second read

$BLNDBearishMed
01

Why it matters

The guidance downgrade reflects macro‑rate pressure and product cost increases, likely weighing on the stock.

02

Market read

Guidance cut and margin decline are material for investors; the stock may react negatively in the short term.

03

What to watch

Potential upside from new large‑bank Autopilot deals that may close in 2027.

Relevance 6/10Novelty 6/10Timing: after-hours

Background

Blend Labs provides a digital mortgage platform; its Autopilot AI product aims to streamline loan processing.

Company-level read

Ticker impact

$BLNDBearishHigh confidence
Context

Blend Labs disclosed Q4 revenue guidance of $27.7‑29.7M, down 8‑15% YoY, and margin pressure from Autopilot costs.

Expected impact

likely pressure as the market prices in lower revenue and margin outlook

Evidence & confidence

The earnings call provided fresh guidance numbers that are materially lower than prior expectations, a primary disclosure for a listed company.

Market effects

Mortgage and fintech sector faces headwinds from higher rates and reduced refinance activity.

U.S. mortgage lenders may see earnings pressure, potentially affecting related REITs.

Limited to U.S. fintech and mortgage markets.

Counterpoint

If Autopilot adoption accelerates faster than expected, the revenue upside could offset guidance cuts.

Key entities

  • Blend Labs Inc

    U.S. fintech firm offering mortgage automation solutions.

Related articles

$BLNDMed

Blend Announces Third Quarter 2026 Financial Results

Blend Labs, Inc. (BLND) filed an SEC Form 8-K — Results of Operations and Financial Condition. Blend Announces Third Quarter 2026 Financial Results November 5, 2026 SAN FRANCISCO -- Blend Labs, Inc. (NYSE: BLND), a leading digital banking platform, today announced its third quarter 2026 financial results. “We had our best sales quarter in more than three years,” said Nima

$BLNDMed

Blend Announces Second Quarter 2026 Financial Results

Blend Labs, Inc. (BLND) filed an SEC Form 8-K — Results of Operations and Financial Condition. Blend Announces Second Quarter 2026 Financial Results August 6, 2026 SAN FRANCISCO -- Blend Labs, Inc. (NYSE: BLND), a leading origination platform for digital banking solutions, today announced its second quarter 2026 financial results. "We delivered Q2 with revenue near the hig

$BLNDMed

British Land reports strong Q1 leasing momentum By Investing.com

British Land reported Q1 FY2027 leasing of 567,000 sq ft, completed at 4.8% above estimated rental value and 8.7% above prior passing rents. An extra 1.1m sq ft is under offer. Near-full occupancy was noted for retail parks and London Urban Logistics. Disposals totaled £83m at 3.2% net initial yield. FY2027 underlying EPS guidance of at least 30.5p was kept.

$NETHighAI 8/10

Cloudflare Just Had Its “Best Quarter Ever” on the Day Tech Crashed

Cloudflare (NET) reported strong Q3 2026 earnings, with revenue of $782.5M (+39% YoY) and non-GAAP EPS of $0.38, beating estimates. Despite a 21.2% weekly decline, shares rose 14.72% after-hours. The company raised full-year revenue guidance to $2.963B-$2.964B and expects GAAP profitability in Q4, earlier than previously forecasted. Key metrics like dollar-based net retention (122%) and remaining performance obligations ($2.877B) also improved.

$SANAHighAI 8/10

Sana Biotechnology Reports Q3 Profit; Advances Cell Therapy Programs Toward Clinical Trials

Sana Biotechnology (SANA) reported Q3 2026 net income of $20.4M, with R&D expenses rising to $33.9M. The company has $121.7M in cash, expecting a runway into mid-2027. SANA advanced cell therapy programs for type 1 diabetes and non-Hodgkin lymphoma, targeting clinical trials in 2026-2027. UP421 showed long-term survival in type 1 diabetes study. SANA stock is up 1.75% to $2.38.